Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCED PRESENTATIONS AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 90% confidence The document is a Hong Kong Stock Exchange voluntary announcement by GenScript Biotech regarding upcoming data presentations at the 2026 ASCO Annual Meeting. It contains no financial statements, no earnings figures, no management discussion, and is simply a corporate/regulatory announcement. This does not qualify as an annual or interim report, proxy, earnings release, or any financial filing type. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-22 English
VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 31 MARCH 2026 OF A LISTED ASSOCIATE - LEGEND BIOTECH CORPORATION
Report Publication Announcement Classification · 88% confidence The document is a voluntary announcement by Genscript Biotech Corporation stating that its associate, Legend Biotech, has filed a Form 6-K with the SEC regarding its Q1 2026 financial results. The text does not contain actual financial statements but provides a link to the published report. This matches the pattern of a Report Publication Announcement (RPA) rather than an actual quarterly report or other filing.
2026-05-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the month ended 30 April 2026. It details changes in authorised share capital, issued shares, share options exercised, and public float sufficiency confirmation. The document is a regulatory submission reporting share capital and share movement data, typical of a regulatory compliance filing rather than a financial report or announcement. It is not an annual or interim report, earnings release, or management discussion. It is also not a proxy, voting result, or capital raising announcement. The document is a regulatory filing reporting share capital movements and public float compliance under HKEX rules, fitting the Regulatory Filings (RNS) category as a general compliance report that does not fit other specific categories.
2026-05-06 English
VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2026
Earnings Release Classification · 60% confidence The document is a voluntary announcement by Genscript Biotech Corporation providing preliminary sales figures for CARVYKTI® for the quarter ended 31 March 2026. It does not represent a full interim (IR) or annual report (10-K or IR), nor is it a governance or board management change notice. It is an initial financial update with key highlights for a quarterly period, matching the definition of an Earnings Release (ER). Q1 2026
2026-04-14 English
FORM OF PROXY FOR 2026 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 94% confidence The document is a Form of Proxy for the 2026 Annual General Meeting, providing voting instructions and solicitation materials to shareholders to appoint proxies and vote on resolutions at the AGM. This matches the definition of Proxy Solicitation & Information Statement.
2026-04-13 English
PROPOSALS FOR (1) GRANTING OF GENERAL MANDATES TO ISSUE NEW SHARES AND TO BUY BACK SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a circular sent to shareholders in advance of the company’s Annual General Meeting. It contains the notice of meeting, detailed explanatory statements for resolutions (issuance mandates, buy-back mandates, re-election of directors, amendments to constitutional documents), and a proxy form. This matches a Proxy Solicitation & Information Statement rather than the AGM presentation itself or the full annual report. Therefore, it is classified as PSI.
2026-04-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.